Better translation from bench to bedside: Breakthroughs in the individualized treatment of cancer

Critical Care Medicine

Volumn 37, Issue SUPPL. 1, 2009, Pages

  Straehle, Carolyn ^a   Cardoso, Fatima ^b   Azambuja, Evandro ^b   Dolci, Stella ^b   Meirsman, Livia ^a   Vantongelen, Kris ^a   Ignatiadis, Michalis ^b   Sotiriou, Christos ^b   Piccart Gebhart, Martine J ^b  

^a Breast International Group   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Biological materials banking; Biomarker; Breast cancer; Clinical trial design; Gene expression profiling; HER2; Individualized treatment; Lapatinib; Mammaprint; Trastuzumab

Indexed keywords

LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; EVOLUTION; HUMAN; MICROARRAY ANALYSIS; ONCOLOGY; PRIORITY JOURNAL; REVIEW; ARTICLE; BREAST TUMOR; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METHODOLOGY; MULTICENTER STUDY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MULTICENTER STUDIES AS TOPIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 58849145235     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181921598     Document Type: Article

References (49)

1. Take aim . . . The Economist, July 7, 2007; 87-88
2. Available at: http://legislative.cancer.gov/ history/phsa/1971. National Cancer Institute. Office of Government and Congressional Relations. The National Cancer Act of 1971
3. Available at: http://www.cancer.org/downloads/ STT/CAFF2007PWSecured.pdf
4. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 2000; 406:747-752
5. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-10874
6. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene-expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-8423
7. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003; 100:10393-10398
8. Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7:96
9. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287-5312
10. Goldhirsch A, Wood WC, Gelber RD, et al: Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol 2007; 18:1133-1144
11. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-2826
12. Available at: http://www.clinicaltrials.gov. ClinicalTrials.gov Identifier: NCT00310180
13. van 't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536
14. van de Vijver MJ, He YD, van 't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009
15. Buyse M, Loi S, van 't Veer LJ, et al: On behalf of the TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192
16. Desmedt C, Piette F, Loi S, et al: On behalf of the TRANSBIG Consortium. Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-centre independent validation series. Clin Cancer Res 2007; 13: 3207-3214
17. Mook S, van 't Veer LJ, Rutgers E, et al: Individualization of therapy using Mamma-Print™: From development to the MINDACT trial. Cancer Genomics Proteomics 2007; 4:147-156
18. Cardoso F, van 't Veer LJ, Rutgers E, et al: Clinical application of the 70-gene profile (MammaPrint™): The MINDACT trial. J Clin Oncol 2008; 10:729-735
19. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph node-negative primary breast cancer. Lancet 2005; 365:671-679
20. Foekens JA, Atkins D, Zhang Y, et al: Multi-center validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006; 24:1665-1671
21. Sotiriou C, Wirapati P, Loi S, et al: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98:262-272
22. Sotiriou C, Piccart MJ: Taking gene-expression profiling to the clinic: When will molecular signatures become relevant to patient care? Nat Rev Cancer 2007; 7:545-553
23. Ignatiadis M, Sotiriou C: Understanding the molecular basis of histological grade. Pathobiology 2008; 75:104-111
24. Bogaerts J, Cardoso F, Buyse M, et al: On behalf of the TRANSBIG consortium. Prospective evaluation of a gene signature as a new prognostic tool in early stage breast cancer: Background and challenges in the design of MINDACT (Microarray In Node negative Disease May Avoid Chemotherapy Trial). Nat Clin Prac Oncol 2006; 3:540-551
25. Available at: http://www.adjuvantonline.com/ index.jsp
26. Hortobagyi G: Trastuzumab in the treatment of breast cancer. N Engl J Med 2006; 353: 1734-1736
27. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182
28. Weil RJ, Palmieri DC, Bronder JL, et al: Breast cancer metastasis to the central nervous system. Am J Pathol 2005; 167:913-920
29. Slamon D, Eiermann W, Robert N, et al: BCIRG 2006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. Breast Cancer Res Treat 2006; 100: abstract 52
30. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684
31. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354:809-820
32. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005; 353:1659-1672
33. Smith I, Procter M, Gelber RD, et al: 2 year follow-up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: A randomized controlled trial. Lancet 2007; 369:29-36
34. Avialable at: http://www.frontier-science.co. uk/index.php
35. Suter TM, Proctere M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25:3859-3865
36. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-2743
37. Perez EA, Byrne JA, Isaac W, et al: Cardiac safety experience in 3127 patients treated with lapatinib. Ann Oncol 2006; 17(Suppl 9):ix70; abstract 1420.
38. Moy B, Goss PE: Lapatinib: Current status and future directions in breast cancer: Oncologist 2006; 11:1047-1057
39. Lin NU, Dieras V, Paul D, et al; EGF105084 Study Group: EGF105084, a Phase II Study of Lapatinib for Brain Metastases in Patients (pts) with HER2+ Breast Cancer Following Trastuzumab (h) Based Systemic Therapy and Cranial Radiotherapy (RT). J Clin Oncol 2007; ASCO Annual Meeting Proceedings; 25, 18S (June 20 Supplement): 1012
40. de Azambuja E, Cardoso F, Meirsman L, et al: La nouvelle generation des etudes cliniques sur le cancer du sein: La bonne drogue et la bonne cible. Bull Cancer 2008; 95: 352-357
41. Abramovitz M, Leyland-Jones B, Dowsett M: Breast International Group Newsletter 2007, Volume 9, Issue 2, page 29
42. Enos R: BIG-North America initiative. Breast International Group Newsletter 2006, Volume 8, Issue 2, pages 4-5
43. Leyland-Jones B, Ambrosone CB, Bartlett JMS, et al: Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank. J Clin Oncol 2008; Oct 27 [Epub ahead of print], 10.1200/JCO.2007.15.1712
44. Cardoso F, Ellis M: MINDACT and TAILORx Collaboration: Validating promising tools for early breast cancer. Breast International Group Newsletter 2007, Volume 9, Issue 3, page 32
45. Twombly R: Slow start to phase 0 as researchers debate value. J Natl Cancer Inst 2006; 98:804-806
46. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3:711-715
47. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216
48. Tuma RS: Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 2006; 98: 1272-1274
49. Ignatiadis M, Xenidis N, Perraki M, et al: Different prognostic value of Cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early breast cancer. J Clin Oncol 2007; 25:5194-5202